<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and Life Sciences : Anatomy : Body Fluids : Blood:" exact="Blood" post="Plasma : Medicine and Health Sciences : Anatomy :"/>
 <result pre="and Health Sciences : Anatomy : Body Fluids : Blood:" exact="Blood" post="Plasma : Biology and Life Sciences : Physiology :"/>
 <result pre="and Life Sciences : Physiology : Body Fluids : Blood:" exact="Blood" post="Plasma : Medicine and Health Sciences : Medical Conditions"/>
 <result pre="Plasma : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: Covid 19 : Biology and"/>
 <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: Covid 19 : Biology and Life"/>
 <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: Covid 19 : Biology and Life Sciences :"/>
 <result pre="Proteins: Antibodies : Medicine and Health Sciences : Oncology :" exact="Cancer" post="Treatment: Antibody Therapy : Medicine and Health Sciences :"/>
 <result pre=": Medicine and Health Sciences : Oncology : Cancer Treatment:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Clinical Medicine"/>
 <result pre="Medicine and Health Sciences : Clinical Medicine : Clinical Immunology:" exact="Antibody" post="Therapy : Biology and Life Sciences : Immunology :"/>
 <result pre=": Biology and Life Sciences : Immunology : Clinical Immunology:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Immunology :"/>
 <result pre=": Medicine and Health Sciences : Immunology : Clinical Immunology:" exact="Antibody" post="Therapy : Medicine and Health Sciences : Medical Conditions"/>
 <result pre="Therapy : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases: Respiratory Infections : Medicine and Health Sciences :"/>
 <result pre="Medicine and Health Sciences : Medical Conditions : Infectious Diseases:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
 <result pre="and Health Sciences : Medical Conditions : Infectious Diseases: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
 <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
 <result pre="Medicine and Health Sciences : Medical Conditions : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Pulmonology :"/>
 <result pre="and Health Sciences : Medical Conditions : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Pulmonology : Respiratory"/>
 <result pre="Respiratory Infections : Medicine and Health Sciences : Pulmonology :" exact="Respiratory" post="Disorders: Respiratory Infections : Medicine and Health Sciences :"/>
 <result pre=": Medicine and Health Sciences : Pulmonology : Respiratory Disorders:" exact="Respiratory" post="Infections : Medicine and Health Sciences : Medical Conditions"/>
 <result pre="Medicine and Health Sciences : Pulmonology : Respiratory Disorders: Respiratory" exact="Infections" post=": Medicine and Health Sciences : Medical Conditions :"/>
 <result pre="Infections : Medicine and Health Sciences : Medical Conditions :" exact="Infectious" post="Diseases : Viral Diseases: SARS : Medicine and Health"/>
 <result pre=": Medicine and Health Sciences : Medical Conditions : Infectious" exact="Diseases" post=": Viral Diseases: SARS : Medicine and Health Sciences"/>
 <result pre="and Health Sciences : Medical Conditions : Infectious Diseases :" exact="Viral" post="Diseases: SARS : Medicine and Health Sciences : Diagnostic"/>
 <result pre=": Diagnostic Medicine : Clinical Laboratory Sciences : Transfusion Medicine:" exact="Blood" post="Transfusion : Medicine and Health Sciences : Hematology :"/>
 <result pre=": Medicine and Health Sciences : Hematology : Transfusion Medicine:" exact="Blood" post="Transfusion : Medicine and Health Sciences : Pharmacology :"/>
 <result pre="for COVID-19: A 19th century remedy for a 21st century" exact="disease" post="http://orcid.org/0000-0001-6079-4277Montelongo-JaureguiDaniel1*http://orcid.org/0000-0001-5600-4367VilaTaissa1http://orcid.org/0000-0001-5286-4562SultanAhmed S.1Jabra-RizkMary Ann12[1], Department of Oncology and Diagnostic Sciences,"/>
 <result pre="publication was supported by the National Institute of Allergy and" exact="Infectious" post="Diseases of the NIH under award number R01AI130170 (NIAID)."/>
 <result pre="was supported by the National Institute of Allergy and Infectious" exact="Diseases" post="of the NIH under award number R01AI130170 (NIAID). The"/>
 <result pre="table-count: page-count: Bridging the gap between now and then Coronavirus" exact="disease" post="2019 (COVID-19) is a viral respiratory disease that mysteriously"/>
 <result pre="between now and then Coronavirus disease 2019 (COVID-19) is a" exact="viral" post="respiratory disease that mysteriously emerged in late December 2019"/>
 <result pre="now and then Coronavirus disease 2019 (COVID-19) is a viral" exact="respiratory" post="disease that mysteriously emerged in late December 2019 in"/>
 <result pre="and then Coronavirus disease 2019 (COVID-19) is a viral respiratory" exact="disease" post="that mysteriously emerged in late December 2019 in Wuhan"/>
 <result pre="coronavirus was identified as the etiologic agent and named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus to"/>
 <result pre="was identified as the etiologic agent and named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the seventh coronavirus to infect"/>
 <result pre="identified as the etiologic agent and named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the seventh coronavirus to infect humans"/>
 <result pre="as remdesivir, are available to help prevent or treat this" exact="disease" post="[5], therefore, convalescent plasma therapy, a century-old medical remedy"/>
 <result pre="viable and immediate option for mitigating the impact of this" exact="disease" post="[6]. Convalescent plasma therapy is a type of passive"/>
 <result pre="recuperated from an infection, and administered to patients with the" exact="infection" post="in order to improve clinical outcome [6]. Although the"/>
 <result pre="COVID-19 and the mainstay of current clinical treatment consisting of" exact="symptomatic" post="management and mechanical ventilation, administering convalescent plasma for treatment"/>
 <result pre="factors) therapy was widely used to treat a range of" exact="infectious diseases" post="such as scarlet fever and pneumococcal pneumonia. In 1890,"/>
 <result pre="a range of infectious diseases such as scarlet fever and" exact="pneumococcal pneumonia." post="In 1890, the physiologists von Behring and Kitasato used"/>
 <result pre="and Kitasato used blood serum from immunized animals to treat" exact="diphtheria" post="and tetanus [13]; subsequently, serum from recovered animals was"/>
 <result pre="used blood serum from immunized animals to treat diphtheria and" exact="tetanus" post="[13]; subsequently, serum from recovered animals was identified as"/>
 <result pre="of convalescent serum gained global recognition and revolutionized the way" exact="infectious diseases" post="were treated, and in 1901, Emil von Behring was"/>
 <result pre="degree of success to treat an array of diseases, including" exact="rheumatic" post="fever [16], scarlet fever [17], mumps [18], measles [18,"/>
 <result pre="array of diseases, including rheumatic fever [16], scarlet fever [17]," exact="mumps" post="[18], measles [18, 19], chickenpox [18], and pneumococcal and"/>
 <result pre="diseases, including rheumatic fever [16], scarlet fever [17], mumps [18]," exact="measles" post="[18, 19], chickenpox [18], and pneumococcal and meningococcal infections"/>
 <result pre="[18], measles [18, 19], chickenpox [18], and pneumococcal and meningococcal" exact="infections" post="[20] (Fig 1). Most notable use was during the"/>
 <result pre="convalescent plasma containing anti-EBOV antibodies. Similarly, in 1979, patients with" exact="Argentine hemorrhagic fever" post="virus treated with convalescent plasma had a lower mortality"/>
 <result pre="Argentine hemorrhagic fever virus treated with convalescent plasma had a" exact="lower" post="mortality rate compared with subjects treated with normal plasma,"/>
 <result pre="and similar results were reported for subsequent epidemics of the" exact="disease" post="[21]. Over the following decades, convalescent plasma therapy was"/>
 <result pre="decades, convalescent plasma therapy was successfully employed during the H1N1" exact="swine influenza" post="pandemic (2009), the H5N1 avian flu epidemic (2003), as"/>
 <result pre="employed during the H1N1 swine influenza pandemic (2009), the H5N1" exact="avian flu" post="epidemic (2003), as well as during the EBOV outbreak"/>
 <result pre="use of convalescent plasma during 2 previous coronavirus epidemics: severe" exact="acute" post="respiratory syndrome (SARS) in 2003, and Middle East respiratory"/>
 <result pre="of convalescent plasma during 2 previous coronavirus epidemics: severe acute" exact="respiratory" post="syndrome (SARS) in 2003, and Middle East respiratory syndrome"/>
 <result pre="convalescent plasma during 2 previous coronavirus epidemics: severe acute respiratory" exact="syndrome" post="(SARS) in 2003, and Middle East respiratory syndrome (MERS)"/>
 <result pre="severe acute respiratory syndrome (SARS) in 2003, and Middle East" exact="respiratory" post="syndrome (MERS) in 2012 [21]. The high degree of"/>
 <result pre="acute respiratory syndrome (SARS) in 2003, and Middle East respiratory" exact="syndrome" post="(MERS) in 2012 [21]. The high degree of success"/>
 <result pre="21–23]. Fig 1 Notable historic uses of antibody therapy against" exact="infectious diseases." post="COVID-19, coronavirus disease 2019; MERS, Middle East respiratory syndrome;"/>
 <result pre="historic uses of antibody therapy against infectious diseases. COVID-19, coronavirus" exact="disease" post="2019; MERS, Middle East respiratory syndrome; SARS, severe acute"/>
 <result pre="against infectious diseases. COVID-19, coronavirus disease 2019; MERS, Middle East" exact="respiratory" post="syndrome; SARS, severe acute respiratory syndrome. Buying time with"/>
 <result pre="coronavirus disease 2019; MERS, Middle East respiratory syndrome; SARS, severe" exact="acute" post="respiratory syndrome. Buying time with the help of the"/>
 <result pre="disease 2019; MERS, Middle East respiratory syndrome; SARS, severe acute" exact="respiratory" post="syndrome. Buying time with the help of the convalescent"/>
 <result pre="antibodies from the blood of someone who recovered from an" exact="infection" post="can be administered to protect or treat another person"/>
 <result pre="is the same as vaccines, making antibodies against a specific" exact="infectious" post="agent readily available. For instance, a vaccine relies on"/>
 <result pre="against SARS-CoV-2 and lacks the presence of other types of" exact="infections" post="[21, 27]. Additionally, only plasma with high anti-SARS-CoV-2 titers"/>
 <result pre="case of prophylaxis, a subject considered at high risk for" exact="infection" post="(because of age or underlying medical conditions or who"/>
 <result pre="can be administered to treat subjects who have contracted the" exact="infection" post="but have not made sufficient antibodies against the virus"/>
 <result pre="virus yet in order to augment their immune response, improve" exact="disease" post="course, and enhance recovery [21]. However, it is important"/>
 <result pre="who recovered from COVID-19 can be administered prophylactically to prevent" exact="infection" post="in vulnerable individuals and those with known exposure to"/>
 <result pre="improve the clinical outcome (Treatment). CP, convalescent plasma; COVID-19, coronavirus" exact="disease" post="2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Convalescent"/>
 <result pre="(Treatment). CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2. Convalescent plasma with neutralizing antibodies"/>
 <result pre="CP, convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2. Convalescent plasma with neutralizing antibodies is"/>
 <result pre="convalescent plasma; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2. Convalescent plasma with neutralizing antibodies is currently"/>
 <result pre="transfusion to rescue a group of 10 patients with severe" exact="disease" post="showed that 1 dose (200 mL) of convalescent plasma"/>
 <result pre="One theoretical complication that may arise is an antibody-mediated proinflammatory" exact="disease" post="enhancement known as antibody-dependent enhancement (ADE), whereby antibodies that"/>
 <result pre="antibody-dependent enhancement (ADE), whereby antibodies that developed during a prior" exact="infection" post="exacerbate severity of the disease [12, 28]. The transfer"/>
 <result pre="that developed during a prior infection exacerbate severity of the" exact="disease" post="[12, 28]. The transfer of these antibodies may aberrantly"/>
 <result pre="recruitment of proinflammatory cytokines and chemokines to the site of" exact="infection" post="and causing severe tissue damage [29–31]. Additionally, the presence"/>
 <result pre="damage [29–31]. Additionally, the presence of non-neutralizing antibodies may exacerbate" exact="viral" post="endocytosis or phagocytosis into host cells via Fc receptors,"/>
 <result pre="endocytosis or phagocytosis into host cells via Fc receptors, potentializing" exact="viral" post="replication [29, 32]. However, although this phenomenon is well"/>
 <result pre="[29, 32]. However, although this phenomenon is well known with" exact="Dengue" post="and other viral diseases, there have not been any"/>
 <result pre="although this phenomenon is well known with Dengue and other" exact="viral" post="diseases, there have not been any reported ADE cases"/>
 <result pre="challenges, the substantial evidence of benefit with use for prior" exact="viral" post="infections offers strong precedent for convalescent plasma as a"/>
 <result pre="the substantial evidence of benefit with use for prior viral" exact="infections" post="offers strong precedent for convalescent plasma as a therapeutic"/>
 <result pre="only on evaluation of the feasibility of plasma treatment for" exact="infectious diseases" post="but also ensure that use of convalescent plasma therapy"/>
 <result pre="Marburg201310.17192/eb2013.0165 15KaufmannSH. Remembering Emil von Behring: from Tetanus Treatment to" exact="Antibody" post="Cooperation with Phagocytes. mBio. 2017;8(1). Epub 2017/03/02. 10.1128/mBio.00117-1728246359 16MooreJJ."/>
 <result pre="Action of Vaccines and of Concentrated Antistreptococcus Serum in Experimental" exact="Streptococcal" post="Arthritis. J Infect Dis. 1914;15(1):215–26. 17Smith DD. Serum treatment"/>
 <result pre="use of convalescent serum in the treatment of measles, chickenpox," exact="mumps" post="and whooping cough, including the prophylactic value of parental"/>
 <result pre="convalescent serum in the treatment of measles, chickenpox, mumps and" exact="whooping cough," post="including the prophylactic value of parental blood: J. M."/>
 <result pre="10.1016/S0097-0522(33)90316-0 PubMed PMID: S0097052233903160. 19KohnJL, KleinIF, SchwarzH. Treatment of preeruptive" exact="measles" post="with convalescent serum. JAMA. 1938;111(26):2361–4. 10.1001/jama.1938.02790520017004 20CasadevallA, ScharffMD. Serum"/>
 <result pre="1938;111(26):2361–4. 10.1001/jama.1938.02790520017004 20CasadevallA, ScharffMD. Serum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapy. Antimicrob Agents Chemother."/>
 <result pre="mortality in patients with severe pandemic influenza A (H1N1) 2009" exact="virus infection." post="Clin Infect Dis. 2011;52(4):447–56. Epub 2011/01/21. 10.1093/cid/ciq106 .21248066 23HungIFN,"/>
 <result pre="CfDCa. Principles of Vaccination. In: Epidemiology and Prevention of Vaccine-Preventable" exact="Diseases" post="[Internet]. Washington, D.C.: Public Health Foundation. 13th. [cited 2020"/>
 <result pre="Pharmacol. 2009;157(2):220–33. Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019"/>
 <result pre="2009;157(2):220–33. Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
 <result pre="Epub 2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The"/>
 <result pre="2009/05/23. 10.1111/j.1476-5381.2009.00190.x19459844 26LaiCC, ShihTP, KoWC, TangHJ, HsuehPR. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic"/>
 <result pre="LiPH, CheungCY, DutryI, LiD, et al.Antibody-dependent enhancement of SARS coronavirus" exact="infection" post="and its role in the pathogenesis of SARS. Hong"/>
 <result pre="Epub 2016/07/09. .27390007 33KatzelnickLC, HarrisE, Participants in the Summit on" exact="Dengue" post="Immune Correlates of P. Immune correlates of protection for"/>
 <result pre="from other coronaviruses?Microbes Infect. 2020;22(2):72–3. Epub 2020/02/25. 10.1016/j.micinf.2020.02.00632092539 35HalsteadSB, O'RourkeEJ." exact="Dengue" post="viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing"/>
 <result pre="2020/02/25. 10.1016/j.micinf.2020.02.00632092539 35HalsteadSB, O'RourkeEJ. Dengue viruses and mononuclear phagocytes. I." exact="Infection" post="enhancement by non-neutralizing antibody. J Exp Med. 1977;146(1):201–17. Epub"/>
 <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
</results>
